• IWR-1-endo: Workflow Optimization for Wnt Signaling Inhibiti

  2026-04-30

  IWR-1-endo empowers precise and reproducible modulation of the Wnt/β-catenin pathway in disease models from colorectal cancer to regenerative biology. This article delivers best-practice protocols, troubleshooting insights, and cross-study integration to maximize data quality in advanced research applications.

• ONX-0914 (PR-957): Advancing Immunoproteasome Inhibition in

  2026-04-30

  ONX-0914 (PR-957) enables precise, selective immunoproteasome inhibition for dissecting cytokine-driven mechanisms in autoimmune and inflammatory disease models. Its robust performance and workflow adaptability, validated in both cellular and animal systems, make it indispensable for advanced immune modulation research.

• Exosomal SNORD52 Drives M2 Macrophage Polarization via JAK2/

  2026-04-29

  This article reviews a recent study elucidating how hepatoma cell-derived exosomal SNORD52 promotes M2 macrophage polarization by activating the JAK2/STAT6 signaling pathway. The findings provide mechanistic insight into the tumor microenvironment of hepatocellular carcinoma and suggest new experimental avenues for dissecting immune modulation in cancer.

• ONX-0914 (PR-957): Precision Immunoproteasome Inhibition in

  2026-04-29

  ONX-0914 (PR-957) enables selective immunoproteasome inhibition for dissecting cytokine regulation and immune cell activation in autoimmune disease models. This guide unpacks advanced workflows, troubleshooting, and reference-driven innovations that set ONX-0914 apart for translational research.

• Carboplatin in Preclinical Oncology: Quantitative Assay Opti

  2026-04-28

  Explore Carboplatin, a platinum-based DNA synthesis inhibitor, through a quantitative lens: this article delivers evidence-backed protocol guidance and practical insights for optimizing cancer research assays—distinct from existing resources by focusing on assay design, reproducibility, and actionable literature synthesis.

• Distinct Apoptotic Pathways in BMECs Induced by Candida krus

  2026-04-28

  Miao et al. (2023) demonstrated that yeast and hypha phases of Candida krusei trigger apoptosis in bovine mammary epithelial cells (BMECs) through separate molecular routes, implicating mitochondrial and death receptor mechanisms. These findings clarify how fungal mastitis develops at a cellular level and highlight the regulatory roles of TLR2/ERK and JNK/ERK signaling, providing a basis for targeted research into bovine mammary gland defense.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-27

  Schwartz’s dissertation critically redefines how in vitro assays capture cancer drug responses, advocating for distinct measurement of proliferative arrest and cell death. These advances support more nuanced interpretation of agents like Axitinib (AG 013736) in angiogenesis inhibition and tumor growth research.

• Lactate-Induced HMGB1 Modification and Exosomal Release in S

  2026-04-27

  This study uncovers how lactate promotes post-translational modifications of HMGB1 in macrophages, facilitating its exosomal release and contributing to the progression of polymicrobial sepsis. The findings reveal novel metabolic-inflammation links and highlight potential intervention points for inflammatory signaling pathway research.

• Carfilzomib (PR-171): Precision Proteasome Inhibition in Mye

  2026-04-26

  Explore how Carfilzomib (PR-171) empowers next-generation proteasome inhibition in multiple myeloma research. This article uniquely connects molecular specificity, emerging biomarker insights, and translational protocol strategies for advanced cancer biology.

• Dimethyloxalylglycine (DMOG): Technical Workflow Guidance

  2026-04-25

  Dimethyloxalylglycine (DMOG) is a cell-permeable inhibitor for controlled hypoxia-inducible factor (HIF) stabilization in mechanistic studies of oxygen sensing, hypoxia signaling, and immune modulation. It is best suited for in vitro and in vivo research workflows where precise, reversible prolyl hydroxylase inhibition is required. DMOG is not intended for diagnostic or therapeutic applications.

• Harnessing SAG to Unlock Hedgehog Signaling in Neurorepair

  2026-04-24

  This thought-leadership piece explores the mechanistic and translational dimensions of Smoothened Agonist (SAG) in Hedgehog pathway research. It connects recent evidence of sex-dependent immune modulation in demyelination with practical guidance for protocol design, while critically examining the competitive landscape and future opportunities for disease modeling and regenerative therapy. This article uniquely bridges mechanistic insight with workflow strategy, providing a roadmap for translational researchers seeking to leverage SAG’s robust and nuanced biology.

• Photothermal-CD47 Blockade Synergy in OSCC: Mechanistic Insi

  2026-04-24

  This article analyzes a recent study demonstrating that photothermal therapy (PTT) enhances the efficacy of CD47 blockade in oral squamous cell carcinoma (OSCC) by inducing calreticulin (CRT) exposure and remodeling the extracellular matrix. These mechanistic advances inform new strategies for combining immuno-oncology and photothermal approaches in solid tumor therapy.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-23

  Schwartz (2022) critically assessed traditional in vitro methods for evaluating anti-cancer drug responses, revealing that commonly used metrics—relative and fractional viability—capture distinct facets of proliferation arrest and cell death. The study’s nuanced findings underscore the importance of using both measures for a more accurate assessment of drug efficacy, with direct implications for angiogenesis and tumor inhibition assays.

• Carfilzomib (PR-171): Advanced Protocols for Proteasome Inhi

  2026-04-23

  Carfilzomib (PR-171) from APExBIO enables precise, irreversible proteasome inhibition—empowering cancer researchers to dissect apoptosis, cell cycle arrest, and resistance mechanisms with nanomolar potency. This guide delivers actionable workflows, troubleshooting insights, and comparisons to emerging combinatorial regimens for translational oncology.

• PPT (Propyl Pyrazole Triol): Precision in ERα-Driven Researc

  2026-04-22

  This article explores the strategic and mechanistic frontiers enabled by PPT (Propyl Pyrazole Triol), a highly selective ERα agonist. Integrating recent biomarker insights from lung adenocarcinoma studies with practical protocol guidance, it positions PPT as an essential translational tool for dissecting estrogen receptor signaling in oncology and beyond.

16779 records 1/1119 page Next 12345 下5页 Last page